Gujarat Themis Biosyn Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 16, 2026
- Posted by: Kunal Singla
- Category: News
The Gujarat Themis Biosyn share price target 2026 is Rs 460, implying approximately 20 percent upside from the current market price of Rs 385.1 (NSE: GUJTHEM). With Q4 FY26 results released in 2026 and Fermentation-Based APIs and Biotechnology tailwinds in focus, the Rs 460 price objective is supported by the FY27 earnings recovery thesis.
Gujarat Themis Biosyn (NSE: GUJTHEM) is a Fermentation-Based APIs and Biotechnology company trading at Rs 385.1 with a market capitalisation of Rs 1,155 crore. Analysts have set the Gujarat Themis Biosyn share price target at Rs 460 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast for Gujarat Themis Biosyn including sector tailwinds, key risks, and the bull and bear scenarios.
Click Here – Get Free Investment Predictions
Gujarat Themis Biosyn Share Price Target 2026: Key Takeaways
- Gujarat Themis Biosyn share price target 2026: Rs 460 (20% upside from CMP Rs 385.1)
- Bull case: Rs 560 | Bear case: Rs 310
- Ticker: GUJTHEM | Sector: Fermentation-Based APIs and Biotechnology | MCap: Rs 1,155 crore
- 52W range: Rs 267 to Rs 617 | PE: 25x
- Key catalyst: Q4 FY26 results and FY27 earnings recovery confirmation in 2026
- Key risk: FY27 earnings miss or sustained FII outflows from Indian equities
Gujarat Themis Biosyn Company Overview
Gujarat Themis Biosyn (NSE: GUJTHEM) is a Kadi-based pharmaceutical biotechnology company manufacturing fermentation-derived APIs including rifampicin, rifabutin, and other specialty antibiotics for domestic and regulated international pharmaceutical markets, listed in 2025. At CMP Rs 385.1 against a 52 week range of Rs 267 to Rs 617, the stock is trading at a meaningful discount to its 52 week high. The trailing PE is 25x and the Rs 460 analyst target implies approximately 20 percent upside from current levels. Compared to peers in biotech APIs like Fermentation Chemicals and Laurus Labs, Gujarat Themis Biosyn is positioned as a potential re-rating candidate on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | GUJTHEM |
| Sector | Fermentation-Based APIs and Biotechnology |
| CMP (2026) | Rs 385.1 |
| 52 Week High | Rs 617 |
| 52 Week Low | Rs 267 |
| Market Cap | Rs 1,155 crore |
| Trailing PE | 25x |
| 12-Month Analyst Target | Rs 460 |
| Bull Case Target | Rs 560 |
| Bear Case Target | Rs 310 |
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks now on Univest
Why Is the Gujarat Themis Biosyn Share Price Target Set at Rs 460 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The Gujarat Themis Biosyn share price target of Rs 460 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for a re-rating. Until FY27 PAT delivery is confirmed, the Rs 460 price objective represents a base case with execution risk attached.
Structural Sector Tailwinds in Fermentation-Based APIs and Biotechnology
The Fermentation-Based APIs and Biotechnology sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Gujarat Themis Biosyn’s position among peers in biotech APIs like Fermentation Chemicals and Laurus Labs creates a structural growth runway. Sustained sector outperformance is one of the key conditions for the Rs 560 bull case to materialise, making sector monitoring essential for investors tracking this stock.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs across sectors and stimulating end market demand. For Gujarat Themis Biosyn, lower interest costs improve the EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 460 analyst consensus. This rate environment is a tailwind across the Fermentation-Based APIs and Biotechnology space.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a favourable policy backdrop for Gujarat Themis Biosyn’s Fermentation-Based APIs and Biotechnology operations. Policy support increases the probability of Gujarat Themis Biosyn achieving its FY27 earnings targets, which in turn supports the Rs 460 price objective set by analysts for 2026.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 25x PE, Gujarat Themis Biosyn is positioned as a beneficiary of institutional reallocation into mid-cap and small-cap Indian stocks. Sustained FII inflow is a necessary condition for re-rating the stock toward the Rs 560 bull case scenario.
Gujarat Themis Biosyn Share Price Targets: Short Term, 12 Month, and Long Term
Short Term Gujarat Themis Biosyn Share Price Target
Near-term support for Gujarat Themis Biosyn is anchored near the 52 week low of Rs 267. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors eyeing a near-term entry can use the 52 week low as a key reference while awaiting the FY27 earnings confirmation that would strengthen the case for the full price objective of Rs 460.
12-Month Gujarat Themis Biosyn Share Price Target 2026
The 12-month Gujarat Themis Biosyn share price target 2026 is Rs 460, implying approximately 20 percent upside from CMP Rs 385.1. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Investors can track live price movement on NSE under the ticker GUJTHEM to assess progress toward this target.
Long Term Gujarat Themis Biosyn Share Price Target: FY27 to FY28
The long term Gujarat Themis Biosyn share price target for the FY27 to FY28 period is Rs 560 in the bull case. Full earnings delivery, re-rating toward higher peer multiples among peers in biotech APIs like Fermentation Chemicals and Laurus Labs, and sustained institutional buying are the three conditions that need to align for the stock to reach the Rs 560 level over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for Gujarat Themis Biosyn in 2026
Bull Case Gujarat Themis Biosyn Share Price Target: Rs 560
The bull case Gujarat Themis Biosyn share price target of Rs 560 materialises when FY27 earnings beat analyst estimates, Fermentation-Based APIs and Biotechnology tailwinds accelerate beyond consensus, and FII flows return strongly to Indian equities. Under this scenario, Gujarat Themis Biosyn re-rates toward higher peer multiples, making Rs 560 achievable within FY28. The current gap between CMP Rs 385.1 and Rs 560 represents approximately 45 percent potential upside.
Bear Case Gujarat Themis Biosyn Share Price Target: Rs 310
The bear case Gujarat Themis Biosyn share price target of Rs 310 materialises if FY27 earnings disappoint, management guides below expectations, or sustained FII outflows depress the broader mid-cap market. Under this scenario, the stock risks testing the 52 week low support near Rs 267, and investors should reassess the investment thesis before adding more capital.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 560 | FY27 earnings beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 460 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 310 | FY27 miss, guidance cut, FII outflows persist |
Key Risks That Could Derail the Gujarat Themis Biosyn 2026 Price Objective
Global Macro and US Tariff Headwinds
The prolonged tariff tension triggered by the US reciprocal tariff announcement in 2026 has reduced FII risk appetite for Indian equities. A global demand slowdown or escalation in trade tensions remains the most prominent macro risk to the Gujarat Themis Biosyn share price target of Rs 460 and could push the stock toward the bear case of Rs 310.
FY27 Earnings Miss and Guidance Risk
Any FY27 earnings miss or downward guidance revision by Gujarat Themis Biosyn’s management would compress valuation multiples. This is the most direct company-specific risk to the Rs 460 analyst price objective. Investors should monitor quarterly results and management commentary closely, especially any signals about demand environment, pricing power, or margin compression in the Fermentation-Based APIs and Biotechnology segment.
Competitive Intensity Among Fermentation-Based APIs and Biotechnology Peers
Intensifying competition from peers in biotech APIs like Fermentation Chemicals and Laurus Labs could compress Gujarat Themis Biosyn’s market share and pricing power over the medium term. This structural risk must be weighed when assessing how defensible the earnings trajectory that underpins the Rs 460 analyst target truly is, particularly as new entrants and imports from China disrupt established market structures.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level operational improvement. For smaller market cap stocks, liquidity constraints can amplify drawdowns significantly. Investors should size positions carefully and maintain stop losses to protect capital if the broader market de-rating continues through FY27.
How to Invest in Gujarat Themis Biosyn: A Step-by-Step Approach
Check the Univest Screener for live data
Before considering any investment based on the Gujarat Themis Biosyn share price target of Rs 460, review the company’s Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, operating margin trends, debt levels, and management commentary on Fermentation-Based APIs and Biotechnology sector demand and competition.
Open a Demat and trading account with a SEBI registered stockbroker to trade Gujarat Themis Biosyn (NSE: GUJTHEM) with regulatory protection. Complete KYC, and before executing any order, study the competitive landscape among peers in biotech APIs like Fermentation Chemicals and Laurus Labs to assess whether Gujarat Themis Biosyn’s competitive position justifies the Rs 460 valuation.
Plan your entry using technical and fundamental triggers. The 52 week low of Rs 267 acts as a key support reference. A confirmed FY27 earnings uptick combined with positive guidance would validate the entry case. Always set a pre-defined stop loss below the 52 week low to limit downside.
Maintain position sizing discipline. Restrict any single stock to 3 to 5 percent of your total equity portfolio. This is especially important in the Fermentation-Based APIs and Biotechnology space where sectoral cycles, regulatory changes, and commodity price swings can amplify volatility beyond initial expectations.
Always consult a SEBI registered financial advisor before making investment decisions based on any analyst price target or market commentary. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track Gujarat Themis Biosyn’s live share price and receive daily stock recommendations from SEBI registered analysts.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on Gujarat Themis Biosyn Share Price Target 2026
What is the Gujarat Themis Biosyn share price target for 2026?
Ans. The Gujarat Themis Biosyn share price target 2026 is Rs 460, implying approximately 20 percent upside from CMP Rs 385.1. The bull case estimate is Rs 560 and the bear case is Rs 310.
What was the Gujarat Themis Biosyn share price target for 2025?
Ans. The 2025 price target for Gujarat Themis Biosyn was based on FY26 earnings projections. The current 2026 analyst consensus stands at Rs 460, reflecting FY27 growth potential from CMP Rs 385.1.
Is Gujarat Themis Biosyn a good investment at Rs 385.1?
Ans. At Rs 385.1, Gujarat Themis Biosyn offers potential upside toward Rs 460 if FY27 earnings recover as projected. Whether the stock is a good buy depends on individual risk appetite, investment horizon, and portfolio goals. Consult a SEBI registered financial advisor before investing.
What are the key risks to the Gujarat Themis Biosyn share price target 2026?
Ans. Key risks to the Gujarat Themis Biosyn share price target of Rs 460 include FY27 earnings miss, global tariff headwinds, sustained FII outflows, and competitive pressure in the Fermentation-Based APIs and Biotechnology sector. Monitoring quarterly results closely is essential.
What is the 52 week high and low of Gujarat Themis Biosyn?
Ans. The 52 week high of Gujarat Themis Biosyn is Rs 617 and the 52 week low is Rs 267. At CMP Rs 385.1, the stock is trading below its 52 week high and offers upside potential toward the Rs 460 analyst price objective.
What are the main growth catalysts for Gujarat Themis Biosyn in 2026?
Ans. Primary growth catalysts for Gujarat Themis Biosyn in 2026 include FY27 PAT recovery, Fermentation-Based APIs and Biotechnology sector tailwinds, RBI rate cuts reducing cost of capital, Union Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does Gujarat Themis Biosyn compare to its peers?
Ans. Gujarat Themis Biosyn operates in Fermentation-Based APIs and Biotechnology alongside peers in biotech APIs like Fermentation Chemicals and Laurus Labs. At CMP Rs 385.1 with MCap Rs 1,155 crore, the company is positioned as a potential re-rating candidate toward the Gujarat Themis Biosyn share price target of Rs 460 on FY27 earnings delivery.
What is the Gujarat Themis Biosyn share price target for 2027?
Ans. The long-term Gujarat Themis Biosyn share price target for FY27 to FY28 is Rs 560 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows. Consult a SEBI registered financial advisor for personalised guidance.
